Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

incyte corp. - INCY

INCY

Close Chg Chg %
70.39 1.33 1.89%

Closed Market

71.72

+1.33 (1.89%)

Volume: 1.52M

Last Updated:

Nov 22, 2024, 4:00 PM EDT

Trade Now

Company Overview: incyte corp. - INCY

INCY Key Data

Open

$70.43

 Day Range

70.33 - 72.00

52 Week Range

50.35 - 83.94

 Market Cap

$13.56B

Shares Outstanding

192.65M

 Public Float

189.60M

Beta

0.71

 Rev. Per Employee

N/A

P/E Ratio

498.51

 EPS

$0.17

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.63M

  

INCY Performance

1 Week
 
 -5.47%
 
1 Month
 
 10.22%
 
3 Months
 
 11.82%
 
1 Year
 
 33.46%
 
5 Years
 
 -19.17%
 

INCY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28
Full Ratings ➔

About incyte corp. - INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

INCY At a Glance

Incyte Corp.
1801 Augustine Cut-Off
Wilmington, Delaware 19803
Phone 1-302-498-6700 Revenue 3.70B
Industry Pharmaceuticals: Major Net Income 597.60M
Sector Health Technology 2023 Sales Growth 8.867%
Fiscal Year-end 12 / 2024 Employees 2,524
View SEC Filings

INCY Valuation

P/E Current 498.513
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 23.738
Price to Sales Ratio 3.839
Price to Book Ratio 2.714
Price to Cash Flow Ratio 28.573
Enterprise Value to EBITDA 14.409
Enterprise Value to Sales 2.864
Total Debt to Enterprise Value 0.005

INCY Efficiency

Revenue/Employee 1,464,203.249
Income Per Employee 236,766.64
Receivables Turnover 4.97
Total Asset Turnover 0.582

INCY Liquidity

Current Ratio 3.745
Quick Ratio 3.694
Cash Ratio 2.948

INCY Profitability

Gross Margin 91.472
Operating Margin 17.636
Pretax Margin 22.573
Net Margin 16.17
Return on Assets 9.407
Return on Equity 12.502
Return on Total Capital 11.399
Return on Invested Capital 12.389

INCY Capital Structure

Total Debt to Total Equity 1.013
Total Debt to Total Capital 1.003
Total Debt to Total Assets 0.771
Long-Term Debt to Equity 0.837
Long-Term Debt to Total Capital 0.829
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Incyte Corp. - INCY

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
2.67B 2.99B 3.39B 3.70B
Sales Growth
+23.53% +11.98% +13.67% +8.87%
Cost of Goods Sold (COGS) incl D&A
161.63M 187.34M 253.35M 315.15M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
51.81M 57.84M 67.86M 82.66M
Depreciation
30.31M 36.34M 46.35M 60.16M
Amortization of Intangibles
21.50M 21.50M 21.50M 22.50M
COGS Growth
+9.75% +15.90% +35.24% +24.39%
Gross Income
2.51B 2.80B 3.14B 3.38B
Gross Income Growth
+24.54% +11.73% +12.23% +7.62%
Gross Profit Margin
+93.94% +93.73% +92.54% +91.47%
2020 2021 2022 2023 5-year trend
SG&A Expense
2.70B 2.16B 2.54B 2.73B
Research & Development
2.22B 1.46B 1.59B 1.63B
Other SG&A
486.62M 703.22M 955.78M 1.10B
SGA Growth
+69.99% -20.02% +17.60% +7.36%
Other Operating Expense
- - - 42.80M
-
Unusual Expense
12.96M 75.83M 107.71M (12.65M)
EBIT after Unusual Expense
(253.25M) 561.71M 491.85M 664.42M
Non Operating Income/Expense
23.21M 10.65M 39.93M 172.35M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.17M 1.91M 2.67M 2.55M
Interest Expense Growth
+17.20% -12.24% +39.73% -4.31%
Gross Interest Expense
2.17M 1.91M 2.67M 2.55M
Interest Capitalized
- - - -
-
Pretax Income
(232.22M) 570.44M 529.12M 834.22M
Pretax Income Growth
-147.70% +345.65% -7.24% +57.66%
Pretax Margin
-8.71% +19.10% +15.59% +22.57%
Income Tax
63.48M (378.14M) 188.46M 236.62M
Income Tax - Current - Domestic
62.48M 83.07M 128.22M 392.51M
Income Tax - Current - Foreign
1.35M 4.40M 3.14M 3.00M
Income Tax - Deferred - Domestic
- (465.53M) 58.40M (159.09M)
Income Tax - Deferred - Foreign
(350.00K) (75.00K) (1.31M) 195.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(295.70M) 948.58M 340.66M 597.60M
Minority Interest Expense
- - - -
-
Net Income
(295.70M) 948.58M 340.66M 597.60M
Net Income Growth
-166.17% +420.79% -64.09% +75.42%
Net Margin Growth
-11.09% +31.76% +10.04% +16.17%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(295.70M) 948.58M 340.66M 597.60M
Preferred Dividends
- - - -
-
Net Income Available to Common
(295.70M) 948.58M 340.66M 597.60M
EPS (Basic)
-1.356 4.3034 1.5345 2.6723
EPS (Basic) Growth
-165.21% +417.36% -64.34% +74.15%
Basic Shares Outstanding
218.07M 220.43M 222.00M 223.63M
EPS (Diluted)
-1.356 4.2715 1.5211 2.6451
EPS (Diluted) Growth
-166.04% +415.01% -64.39% +73.89%
Diluted Shares Outstanding
218.07M 222.07M 223.96M 225.93M
EBITDA
(188.48M) 695.38M 667.42M 734.43M
EBITDA Growth
-139.58% +468.93% -4.02% +10.04%
EBITDA Margin
-7.07% +23.29% +19.66% +19.87%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 77.55
Number of Ratings 28 Current Quarters Estimate 1.495
FY Report Date 12 / 2024 Current Year's Estimate 1.266
Last Quarter’s Earnings 1.07 Median PE on CY Estimate N/A
Year Ago Earnings 3.526 Next Fiscal Year Estimate 5.919
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 19 6 17 19
Mean Estimate 1.50 1.12 1.27 5.92
High Estimates 1.91 1.33 1.65 7.88
Low Estimate 1.06 0.78 0.71 4.09
Coefficient of Variance 16.76 17.74 18.99 15.27

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 12 11
OVERWEIGHT 2 2 2
HOLD 14 13 12
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Incyte Corp. - INCY

Date Name Shares Transaction Value
Oct 4, 2024 Sheila A. Denton EVP & General Counsel 30,343 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $67.63 per share 2,052,097.09
Sep 17, 2024 Jonathan Elliott Dickinson EVP, General Manager, Europe 43,723 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $62.3 per share 2,723,942.90
Sep 17, 2024 Thomas Tray Principal Accounting Officer 24,825 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $62.94 per share 1,562,485.50
Sep 17, 2024 Jonathan Elliott Dickinson EVP, General Manager, Europe 36,390 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $62.37 per share 2,269,644.30
Sep 17, 2024 Thomas Tray Principal Accounting Officer 24,443 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $63.37 per share 1,548,952.91
Jul 18, 2024 Christiana Stamoulis EVP & Chief Financial Officer 95,197 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $64.25 per share 6,116,407.25
Jul 18, 2024 Paula J. Swain EVP, Human Resources 86,625 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Steven H. Stein EVP & Chief Medical Officer 31,088 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Herve Hoppenot Chairman / CEO; Director 501,635 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Matteo Trotta EVP, GM, Dermatology US 5,921 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Barry P Flannelly EVP & General Manager US 58,042 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $64.19 per share 3,725,715.98
Jul 18, 2024 Barry P Flannelly EVP & General Manager US 59,348 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $64.25 per share 3,813,109.00
Jul 18, 2024 Barry P Flannelly EVP & General Manager US 60,459 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Christiana Stamoulis EVP & Chief Financial Officer 28,127 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Steven H. Stein EVP & Chief Medical Officer 103,174 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Christiana Stamoulis EVP & Chief Financial Officer 96,145 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Paula J. Swain EVP, Human Resources 16,284 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Vijay Iyengar EVP, GMAPPS 52,821 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Pablo J. Cagnoni President, R&D 44,411 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Pablo J. Cagnoni President, R&D 221,919 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Incyte Corp. in the News